Reimbursement Approval from Health Insurers in Saudi Arabia

NZX/ASX Announcement 12 February 2024 TruScreen Secures Reimbursement Approval from Health Insurers in Saudi Arabia Highlights o TruScreen screening procedure is approved for reimbursement by most private health insurance companies in Saudi Arabia, o The approval reduces the costs for women choosing TruScreen over conventional Pap Smear in private hospitals. TruScreen Group Limited (NZX/ASX:TRU) is pleased to announce its distributor, Bettalife, in Saudi Arabia has successfully obtained reimbursement approval from most health insurance companies in the country. With reimbursement in place, women who are insured and opt for TruScreen over the conventional Pap Smear will receive TruScreen at a cheaper price point, making the advanced screening technology more accessible and cost-effective. The subsidised costs for TruScreen usage will drive adoption within the private healthcare sector. Private health insurance is growing in Saudi Arabia, and is obligated for non-Saudis. Dr. Beata Edling, the CEO of TruScreen, expressed enthusiasm about the private insurer reimbursement approvals, stating, "This reflects the growing acceptance of TruScreen technology world-wide and demonstrates our dedication to providing accessible and reliable cervical cancer screening. This approval will benefit women in Saudi Arabia and contribute to the continued success and expansion of TruScreen in the region." "TruScreen's achievement of private insurers' reimbursement approval in Saudi Arabia is a testament to the company's commitment to advancing women's healthcare globally, and achieving our ultimate goal, 'A world without cervical cancer'." This announcement has been approved by the Board. ENDS For more information, visit www.truscreen.com or contact: Beata Edling Chief Executive Officer beataedling@truscreen.com Guy Robertson Chief Financial Officer guyrobertson@truscreen.com End CA:00425972 For:TRU Type:GENERAL Time:2024-02-12 08:30:22